Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 30018083
Miess E, et al. (2018) Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal 11 30018083
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T370-p - MOR-1 (mouse)
Modsite: sARIRQNtREHPstA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo immunoassay, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK2 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
KINASE GRK3 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
morphine increase
DAMGO increase
siRNA decrease GRK2/3 siRNA
Cmpd101 decrease
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ARRB2 (human) Induces FRET

S375-p - MOR-1 (mouse)
Modsite: QNtREHPstANtVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo immunoassay, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK2 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
KINASE GRK3 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
morphine increase
DAMGO increase
siRNA decrease GRK2/3 siRNA
Cmpd101 decrease
Downstream Regulation
Effect of modification (function):  molecular association, regulation, phosphorylation, receptor desensitization, induced
Effect of modification (process):  endocytosis, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ARRB2 (human) Induces FRET
Comments:  induces phosphorylation of other sites in the protein

T376-p - MOR-1 (mouse)
Modsite: NtREHPstANtVDRT SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T378‑p, MOR‑1 iso5 (human): T378‑p, MOR‑1 (mouse): T376‑p, MOR‑1 (rat): T376‑p
Characterization
Methods used to characterize site in vivo immunoassay, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
KINASE GRK2 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
morphine increase
DAMGO increase
siRNA decrease GRK2/3 siRNA
Cmpd101 decrease
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ARRB2 (human) Induces FRET

T379-p - MOR-1 (mouse)
Modsite: EHPstANtVDRTNHQ SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T381‑p, MOR‑1 iso5 (human): T381‑p, MOR‑1 (mouse): T379‑p, MOR‑1 (rat): T379‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
KINASE GRK2 (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
morphine increase
DAMGO increase
siRNA decrease GRK2/3 siRNA
Cmpd101 decrease
Downstream Regulation
Effect of modification (function):  molecular association, regulation, receptor desensitization, induced
Effect of modification (process):  endocytosis, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ARRB2 (human) Induces FRET